RU2019138568A - Частицы, содержащие производное билирубина и металл - Google Patents
Частицы, содержащие производное билирубина и металл Download PDFInfo
- Publication number
- RU2019138568A RU2019138568A RU2019138568A RU2019138568A RU2019138568A RU 2019138568 A RU2019138568 A RU 2019138568A RU 2019138568 A RU2019138568 A RU 2019138568A RU 2019138568 A RU2019138568 A RU 2019138568A RU 2019138568 A RU2019138568 A RU 2019138568A
- Authority
- RU
- Russia
- Prior art keywords
- bilirubin
- derivative
- metal
- particle
- poly
- Prior art date
Links
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical class N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 title claims 29
- 239000002245 particle Substances 0.000 title claims 14
- 229910052751 metal Inorganic materials 0.000 claims 11
- 239000002184 metal Substances 0.000 claims 11
- -1 platinum ion Chemical class 0.000 claims 7
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 5
- 229920000954 Polyglycolide Polymers 0.000 claims 4
- 150000002433 hydrophilic molecules Chemical class 0.000 claims 3
- 229910052697 platinum Inorganic materials 0.000 claims 3
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
- 229910052748 manganese Inorganic materials 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229920001444 polymaleic acid Chemical class 0.000 claims 2
- 239000003642 reactive oxygen metabolite Substances 0.000 claims 2
- 229910052701 rubidium Inorganic materials 0.000 claims 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 229910052688 Gadolinium Inorganic materials 0.000 claims 1
- 229920002527 Glycogen Polymers 0.000 claims 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 229920002732 Polyanhydride Chemical class 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229920002873 Polyethylenimine Polymers 0.000 claims 1
- 108010039918 Polylysine Proteins 0.000 claims 1
- 229920001710 Polyorthoester Polymers 0.000 claims 1
- 239000004793 Polystyrene Substances 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 claims 1
- 229910052792 caesium Inorganic materials 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229910052804 chromium Inorganic materials 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 229910052733 gallium Inorganic materials 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 229940096919 glycogen Drugs 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 229910052738 indium Inorganic materials 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 claims 1
- 150000003951 lactams Chemical group 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 229910052747 lanthanoid Inorganic materials 0.000 claims 1
- 150000002602 lanthanoids Chemical class 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 239000011572 manganese Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229910021645 metal ion Inorganic materials 0.000 claims 1
- 229910052750 molybdenum Inorganic materials 0.000 claims 1
- 150000002772 monosaccharides Chemical class 0.000 claims 1
- 229950007221 nedaplatin Drugs 0.000 claims 1
- 229910052759 nickel Inorganic materials 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 229910052763 palladium Inorganic materials 0.000 claims 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 claims 1
- 239000002745 poly(ortho ester) Substances 0.000 claims 1
- 229920001610 polycaprolactone Chemical class 0.000 claims 1
- 239000004632 polycaprolactone Chemical class 0.000 claims 1
- 229920000515 polycarbonate Polymers 0.000 claims 1
- 239000004417 polycarbonate Substances 0.000 claims 1
- 229920000867 polyelectrolyte Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920000656 polylysine Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920006389 polyphenyl polymer Polymers 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 229920002223 polystyrene Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 229910052709 silver Inorganic materials 0.000 claims 1
- 239000010944 silver (metal) Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 229910052712 strontium Inorganic materials 0.000 claims 1
- 229910052713 technetium Inorganic materials 0.000 claims 1
- 229920001567 vinyl ester resin Polymers 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 229910052727 yttrium Inorganic materials 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
- 229910052726 zirconium Inorganic materials 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A61K47/6915—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the form being a liposome with polymerisable or polymerized bilayer-forming substances, e.g. polymersomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K51/0451—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. phorphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/242—Gold; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
- A61K49/0414—Particles, beads, capsules or spheres
- A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
- A61K49/0428—Surface-modified nanoparticles, e.g. immuno-nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
- A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
- A61K49/186—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA the organic macromolecular compound being polyethyleneglycol [PEG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
- A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
- A61K51/1234—Liposomes
- A61K51/1237—Polymersomes, i.e. liposomes with polymerisable or polymerized bilayer-forming substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/728—Bilirubin; including biliverdin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Radiology & Medical Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (17)
1. Частица производного билирубина, содержащая производное билирубина и металл.
2. Частица производного билирубина по п. 1, отличающаяся тем, что указанная частица производного билирубина образована посредством координационной связи указанного производного билирубина и указанного металла.
3. Частица производного билирубина по п. 1, отличающаяся тем, указанная координационная связь образована между указанным металлом и карбоксильной группой, лактамной группой или пиррольным кольцом указанного производного билирубина.
4. Частица производного билирубина по любому из пп. 1 - 3, отличающаяся тем, что указанный металл представляет собой ион металла или соединение металла, выбранного из группы, состоящей из Cu, Ga, Rb, Zr, Y, Tc, In, Ti, Gd, Mn, Fe, Au, Pt, Pd, Ag, Co, Mn, Zn, Gd, Mo, Ni, Fe, Cr, Na, K, Rb, Cs, Mg, Ca, Sr, Ba, Ra и лантаноидов.
5. Частица производного билирубина по любому из пп. 1 - 3, отличающаяся тем, что указанный металл представляет собой суперпарамагнитную наночастицу оксида железа (SPION) или наночастицу золота.
6. Частица производного билирубина по любому из пп. 1 - 3, отличающаяся тем, что указанный металл представляет собой ион платины (Pt) или противораковое лекарственное средство на основе платины, выбранное из группы, состоящей из цисплатина, карбоплатина, оксалиплатина, недаплатина и гептаплатина.
7. Частица производного билирубина по любому из пп.1 - 3, отличающаяся тем, что указанный металл представляет собой радиоактивный изотоп, выбранный из группы, состоящей из 64Cu, 68Ga, 82Rb, 89Zr, 90Y, 99mTc, 111In и 201TI.
8. Частица производного билирубина по любому из пп. 1 - 3, отличающаяся тем, что указанное производное билирубина представляет собой производное, в котором гидрофильная молекула конъюгирована с билирубином.
9. Частица производного билирубина по п. 8, отличающаяся тем, что указанная гидрофильная молекула выбрана из группы, состоящей из декстрана, карбодекстрана, полисахарида, циклодекстрана, плюроника, целлюлозы, крахмала, гликогена, углевода, моносахарида, бисахарида и олигосахарида, полифосфагена, полилактида, сополимера молочной кислоты и гликолевой кислоты, поликапролактона, полиангидрида, полималеиновой кислоты и производных полималеиновой кислоты, полиалкилцианоакрилата, полигидроксибутилата, поликарбоната, полиортоэфира, полиэтиленгликоля, полипропиленгликоля, полиэтиленимина, поли-L-лизина, полигликолида, полиметакрилата, поливинилпирролидона, поли[акрилата], поли[акриламида], полимера сложного винилового эфира, полимера винилового спирта, полистирола, полиоксида, полиэлектролита, поли[1-нитропропилена], поли[N-винилпирролидона], поли[виниламина], поли[бета-гидроксиэтилметакрилата], полиэтиленоксида, поли[этиленоксид-b-пропиленоксид], полилизина и пептида.
10. Композиция, содержащая частицы производного билирубина по любому из пп. 1 - 9.
11. Композиция по п. 10, представляющая собой композицию контрастного агента для диагностики при помощи изображения.
12. Композиция по п. 10, представляющая собой фармацевтическую композицию для лечения рака.
13. Композиция по п. 10, представляющая собой фармацевтическую композицию для лечения и диагностики воспалительного заболевания.
14. Композиция по п. 10, предназначенная для обнаружения активных форм кислорода (АФК).
15. Способ получения частицы производного билирубина, содержащей металл и производное билирубина, включающий стадии:
(а) конъюгирование билирубина с гидрофильной молекулой с получением производного билирубина; и
(b) координирование указанного производного билирубина и металла с получением частицы производного билирубина, содержащей инкапсулированный металл.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2017-0059597 | 2017-05-12 | ||
KR20170059597 | 2017-05-12 | ||
PCT/KR2018/005515 WO2018208137A2 (ko) | 2017-05-12 | 2018-05-14 | 빌리루빈 유도체 및 금속을 포함하는 입자 |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2019138568A true RU2019138568A (ru) | 2021-06-15 |
RU2019138568A3 RU2019138568A3 (ru) | 2021-06-15 |
RU2756753C2 RU2756753C2 (ru) | 2021-10-05 |
Family
ID=64104730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2019138568A RU2756753C2 (ru) | 2017-05-12 | 2018-05-14 | Частицы, содержащие производное билирубина и металл |
Country Status (10)
Country | Link |
---|---|
US (1) | US11896681B2 (ru) |
EP (1) | EP3622969A4 (ru) |
JP (2) | JP2020523404A (ru) |
KR (2) | KR102254093B1 (ru) |
CN (1) | CN111182926A (ru) |
AU (1) | AU2018267526B2 (ru) |
BR (1) | BR112019023725A2 (ru) |
CA (1) | CA3063337A1 (ru) |
RU (1) | RU2756753C2 (ru) |
WO (1) | WO2018208137A2 (ru) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102056948B1 (ko) * | 2018-02-05 | 2019-12-17 | 주식회사 빌릭스 | 빌리루빈 유도체 기반의 진단 및 치료용 초음파 조영제 |
KR102591787B1 (ko) * | 2021-01-13 | 2023-10-20 | 한국과학기술원 | 키토산-빌리루빈 접합체를 포함하는 입자 및 이를 포함하는 약제학적 조성물 |
CN112972392B (zh) * | 2021-03-10 | 2022-06-21 | 温州医科大学附属第二医院(温州医科大学附属育英儿童医院) | 一种胆红素纳米颗粒及其制备和应用 |
CN115317437B (zh) * | 2021-05-11 | 2023-09-08 | 中国科学院上海硅酸盐研究所 | 一种基于胆红素纳米材料的胰岛素递送微针及其制备方法 |
CN113456836B (zh) * | 2021-07-07 | 2022-09-16 | 中国科学院精密测量科学与技术创新研究院 | 一种锰-血红素配位聚合物纳米颗粒及其制备方法和应用 |
WO2024010353A1 (ko) * | 2022-07-05 | 2024-01-11 | 주식회사 빌릭스 | 페길화된 빌리루빈을 포함하는 염증성 질환의 예방 또는 치료용 약학 조성물 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2412623A1 (en) * | 2000-06-14 | 2001-12-20 | Brian J. Day | Tetrapyrroles |
WO2007103427A2 (en) * | 2006-03-06 | 2007-09-13 | Wang Xiang H | Medical use of bilirubin and its structural analogues |
WO2011019817A2 (en) | 2009-08-11 | 2011-02-17 | Cornell Research Foundation, Inc. | Nanoparticles and methods of generating coherent emission therefrom |
WO2015099492A1 (ko) * | 2013-12-27 | 2015-07-02 | 한국과학기술원 | 빌리루빈 나노입자, 이의 용도 및 제조방법 |
WO2017070676A1 (en) | 2015-10-23 | 2017-04-27 | Massachusetts Instittue Of Technology | Nanoparticles comprising a metal core surrounded by a monolayer for lymph node targeting |
KR20170059597A (ko) | 2015-11-23 | 2017-05-31 | (주)이노큐디 | 멀티 광 스펙트럼의 복합 양자점을 혼합한 캡슐 |
-
2018
- 2018-04-26 KR KR1020180048650A patent/KR102254093B1/ko active IP Right Grant
- 2018-05-14 CN CN201880042226.4A patent/CN111182926A/zh active Pending
- 2018-05-14 US US16/343,043 patent/US11896681B2/en active Active
- 2018-05-14 JP JP2020513477A patent/JP2020523404A/ja active Pending
- 2018-05-14 BR BR112019023725-9A patent/BR112019023725A2/pt unknown
- 2018-05-14 EP EP18799160.9A patent/EP3622969A4/en active Pending
- 2018-05-14 WO PCT/KR2018/005515 patent/WO2018208137A2/ko active Application Filing
- 2018-05-14 AU AU2018267526A patent/AU2018267526B2/en active Active
- 2018-05-14 RU RU2019138568A patent/RU2756753C2/ru active
- 2018-05-14 CA CA3063337A patent/CA3063337A1/en active Pending
-
2021
- 2021-05-13 KR KR1020210062003A patent/KR102292960B1/ko active IP Right Grant
-
2022
- 2022-12-23 JP JP2022206483A patent/JP2023052056A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2756753C2 (ru) | 2021-10-05 |
JP2023052056A (ja) | 2023-04-11 |
US20200230261A1 (en) | 2020-07-23 |
WO2018208137A9 (ko) | 2019-04-18 |
JP2020523404A (ja) | 2020-08-06 |
CN111182926A (zh) | 2020-05-19 |
EP3622969A4 (en) | 2020-05-27 |
CA3063337A1 (en) | 2019-12-05 |
KR20180124727A (ko) | 2018-11-21 |
KR102254093B1 (ko) | 2021-05-20 |
RU2019138568A3 (ru) | 2021-06-15 |
EP3622969A2 (en) | 2020-03-18 |
US11896681B2 (en) | 2024-02-13 |
BR112019023725A2 (pt) | 2020-05-26 |
AU2018267526B2 (en) | 2021-09-16 |
WO2018208137A3 (ko) | 2019-03-28 |
WO2018208137A2 (ko) | 2018-11-15 |
KR102292960B1 (ko) | 2021-08-24 |
AU2018267526A1 (en) | 2020-01-02 |
KR20210059683A (ko) | 2021-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2019138568A (ru) | Частицы, содержащие производное билирубина и металл | |
Cao et al. | Metal-organic framework (MOF)-based drug delivery | |
Kwon et al. | Large‐scale synthesis and medical applications of uniform‐sized metal oxide nanoparticles | |
Ali et al. | Noble metals based bimetallic and trimetallic nanoparticles: controlled synthesis, antimicrobial and anticancer applications | |
Bahrani et al. | Zinc-based metal–organic frameworks as nontoxic and biodegradable platforms for biomedical applications: review study | |
Zelepukin et al. | Laser-synthesized TiN nanoparticles for biomedical applications: Evaluation of safety, biodistribution and pharmacokinetics | |
De La Vega et al. | Utilization of nanoparticles as X‐ray contrast agents for diagnostic imaging applications | |
Liu et al. | Cisplatin loaded hyaluronic acid modified TiO2 nanoparticles for neoadjuvant chemotherapy of ovarian cancer | |
EP2956119B1 (en) | Nanoparticle delivery compositions | |
Mishra et al. | Doxorubicin-conjugated bimetallic silver–gadolinium nanoalloy for multimodal MRI-CT-optical imaging and pH-responsive drug release | |
Mishra et al. | A bimetallic silver–neodymium theranostic nanoparticle with multimodal NIR/MRI/CT imaging and combined chemo-photothermal therapy | |
Mansur et al. | Supramolecular magnetonanohybrids for multimodal targeted therapy of triple-negative breast cancer cells | |
CN105358136B (zh) | 超分子磁性纳米粒子 | |
Al-Musawi et al. | Folated-nanocarrier for paclitaxel drug delivery in leukemia cancer therapy | |
Pornpitchanarong et al. | Synthesis of novel N-vinylpyrrolidone/acrylic acid nanoparticles as drug delivery carriers of cisplatin to cancer cells | |
Telegeev et al. | Dextran‐Polyacrylamide as Matrices for Creation of Anticancer Nanocomposite | |
Mishra et al. | Microwave synthesis of chitosan capped silver–dysprosium bimetallic nanoparticles: a potential nanotheranosis device | |
Diem et al. | Synthesis of Gold Nanoparticles Stabilized in Dextran Solution by Gamma Co‐60 Ray Irradiation and Preparation of Gold Nanoparticles/Dextran Powder | |
Ghosh et al. | Target delivery of photo-triggered nanocarrier for externally activated chemo-photodynamic therapy of prostate cancer | |
KR20190094699A (ko) | 빌리루빈 유도체 기반의 진단 및 치료용 초음파 조영제 | |
CA2901050C (en) | Caged platinum nanoclusters for anticancer chemotherapeutics | |
Arkaban et al. | Imaging and therapeutic capabilities of the AuNPs@ MnCO3/Mn3O4, coated with PAA and integrated with folic acid, doxorubicin and propidium iodide for murine breast cancer | |
Castillo et al. | Exploring factors for the design of nanoparticles as drug delivery vectors | |
Akl et al. | Biodegradable functionalized magnetite nanoparticles as binary-targeting carrier for breast carcinoma | |
CN104940951B (zh) | 一种磁性还原响应性抗肿瘤药物载体的制备方法 |